Market News AIOpen the app

RCUS stock news · Arcus Biosciences, Inc.

Stories about Arcus Biosciences, Inc. (RCUS) from the last 90 days, each explained in plain English with whether the news reads good or bad for the company.

Get alerts for RCUS

Follow Arcus Biosciences, Inc. (RCUS) free. When we publish a story about it, you get the plain-English explanation as an alert.

Get alerts for RCUS
Free on the App Store and Google Play, or on the web.
  1. Nov 3, 2026, 6:49 PM ET · Market

    Arcus Biosciences will share its third quarter 2026 sales results on November 4, 2026.

    Neutral

    Arcus set Nov. 4, 2026, to report third-quarter results; analysts estimate $7.58 million in sales and a $0.89-per-share loss. No results are reported, so this does not change its outlook.

  2. Oct 23, 2026, 6:11 PM ET · Market

    Arcus Biosciences finished selling 16,428,572 shares, bringing in about $269.7 million.

    Neutral

    Arcus raised about $270 million by issuing 16.4 million shares. The added cash helps, but the larger share count pulls the other way, so this filing alone leaves its outlook unchanged.

  3. Oct 21, 2026, 7:46 AM ET · Market

    Wedbush raised its target price for Arcus Biosciences to $49 from $43 and still thinks it will do well.

    Good for RCUS

    Wedbush raised its Arcus share target and kept its Outperform rating. That is a favorable outside view, though the story adds no new trial results.